LEDA LEME TALIB
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina
LIM/27 - Laboratório de Neurociências, Hospital das Clínicas, Faculdade de Medicina
LIM/27 - Laboratório de Neurociências, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms(2017) SCHMITT, Andrea; MARTINS-DE-SOUZA, Daniel; AKBARIAN, Schahram; CASSOLI, Juliana S.; EHRENREICH, Hannelore; FISCHER, Andre; FONTEH, Alfred; GATTAZ, Wagner F.; GAWLIK, Michael; GERLACH, Manfred; GRUNBLATT, Edna; HALENE, Tobias; HASAN, Alkomiet; HASHIMOTO, Kenij; KIM, Yong-Ku; KIRCHNER, Sophie-Kathrin; KORNHUBER, Johannes; KRAUS, Theo F. J.; MALCHOW, Berend; NASCIMENTO, Juliana M.; ROSSNER, Moritz; SCHWARZ, Markus; STEINER, Johann; TALIB, Leda; THIBAUT, Florence; RIEDERER, Peter; FALKAI, PeterObjectives: Despite progress in identifying molecular pathophysiological processes in schizophrenia, valid biomarkers are lacking for both the disease and treatment response. Methods: This comprehensive review summarises recent efforts to identify molecular mechanisms on the level of protein and gene expression and epigenetics, including DNA methylation, histone modifications and micro RNA expression. Furthermore, it summarises recent findings of alterations in lipid mediators and highlights inflammatory processes. The potential that this research will identify biomarkers of schizophrenia is discussed. Results: Recent studies have not identified clear biomarkers for schizophrenia. Although several molecular pathways have emerged as potential candidates for future research, a complete understanding of these metabolic pathways is required to reveal better treatment modalities for this disabling condition. Conclusions: Large longitudinal cohort studies are essential that pair a thorough phenotypic and clinical evaluation for example with gene expression and proteome analysis in blood at multiple time points. This approach might identify biomarkers that allow patients to be stratified according to treatment response and ideally also allow treatment response to be predicted. Improved knowledge of molecular pathways and epigenetic mechanisms, including their potential association with environmental influences, will facilitate the discovery of biomarkers that could ultimately be effective tools in clinical practice.
- Plasma Metabolite Profiles in First Episode Psychosis: Exploring Symptoms Heterogeneity/Severity in Schizophrenia and Bipolar Disorder Cohorts(2020) JOAQUIM, Helena P. G.; COSTA, Alana C.; TALIB, Leda L.; DETHLOFF, Frederik; SERPA, Mauricio H.; ZANETTI, Marcus V.; BILT, Martinus van de; TURCK, Christoph W.Introduction The first symptoms of psychosis are frequently shared amongst several neuropsychiatry disorders, which makes the differentiation by clinical diagnosis challenging. Early recognition of symptoms is important in the management of psychosis. Therefore, the implementation of molecular biomarkers will be crucial for transforming the currently used diagnostic and therapeutic approach, improving insights into the underlying biological processes and clinical management. Objectives To define a set of metabolites that supports diagnosis or prognosis of schizophrenia (SCZ) and bipolar disorder (BD) at first onset psychosis. Methods Plasma samples from 55 drug-naive patients, 28 SCZ and 27 BD, and 42 healthy controls (HC). All participants underwent a seminaturalistic treatment regimen, clinically evaluated on a weekly basis until achieving clinical remission. All clinical or sociodemographic aspects considered for this study were equivalent between the groups at first-onset psychosis time point. The plasma samples were analyzed by untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) using reversed-phase and hydrophilic interaction chromatography. The acquired molecular features were analyzed with MetaboAnalyst. Results We identified two patient groups with different metabolite profiles. Both groups are composed of SCZ and BD patients. We found differences between these two groups regarding general symptoms of PANSS score after remission (p = 0.008), and the improvement of general symptoms (delta of the score at remission minus the baseline) (-0.50 vs. -0.33, p = 0.019). Conclusion Our results suggest that plasma metabolite profiles cluster clinical remission phenotypes based on PANSS general psychopathology scores.
- The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers(2011) MATTSSON, Niklas; ANDREASSON, Ulf; PERSSON, Staffan; ARAI, Hiroyuki; BATISH, Sat Dev; BERNARDINI, Sergio; BOCCHIO-CHIAVETTO, Luisella; BLANKENSTEIN, Marinus A.; CARRILLO, Maria C.; CHALBOT, Sonia; COART, Els; CHIASSERINI, Davide; CUTLER, Neal; DAHLFORS, Gunilla; DULLER, Stefan; FAGAN, Anne M.; FORLENZA, Orestes; FRISONI, Giovanni B.; GALASKO, Douglas; GALIMBERTI, Daniela; HAMPEL, Harald; HANDBERG, Aase; HENEKA, Michael T.; HERSKOVITS, Adrianna Z.; HERUKKA, Sanna-Kaisa; HOLTZMAN, David M.; HUMPEL, Christian; HYMAN, Bradley T.; IQBAL, Khalid; JUCKER, Mathias; KAESER, Stephan A.; KAISER, Elmar; KAPAKI, Elisabeth; KIDD, Daniel; KLIVENYI, Peter; KNUDSEN, Cindy S.; KUMMER, Markus P.; LUI, James; LLADO, Albert; LEWCZUK, Piotr; LI, Qiao-Xin; MARTINS, Ralph; MASTERS, Colin; MCAULIFFE, John; MERCKEN, Marc; MOGHEKAR, Abhay; MOLINUEVO, Jose Luis; MONTINE, Thomas J.; NOWATZKE, William; O'BRIEN, Richard; OTTO, Markus; PARASKEVAS, George P.; PARNETTI, Lucilla; PETERSEN, Ronald C.; PRVULOVIC, David; REUS, Herman P. M. de; RISSMAN, Robert A.; SCARPINI, Elio; STEFANI, Alessandro; SOININEN, Hilkka; SCHROEDER, Johannes; SHAW, Leslie M.; SKINNINGSRUD, Anders; SKROGSTAD, Brith; SPREER, Annette; TALIB, Leda; TEUNISSEN, Charlotte; TROJANOWSKI, John Q.; TUMANI, Hayrettin; UMEK, Robert M.; BROECK, Bianca Van; VANDERSTICHELE, Hugo; VECSEI, Laszlo; VERBEEK, Marcel M.; WINDISCH, Manfred; ZHANG, Jing; ZETTERBERG, Henrik; BLENNOW, KajBackground: The cerebrospinal fluid (CSF) biomarkers amyloid beta (A beta)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program. Methods: The program is open for laboratories using commercially available kits for A beta, T-tau, or P-tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Molndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples. Results: Forty laboratories participated. Twenty-six used INNOTEST enzyme-linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO-BIA AlzBio3 kit (both measure A beta-(1-42), P-tau(181P), and T-tau), and 5 used Mesa Scale Discovery with the A beta triplex (A beta N-42, A beta N-40, and A beta N-38) or T-tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within-laboratory precisions differed considerably between biomarkers within individual laboratories. Conclusions: Measurements of CSF AD biomarkers show large between-laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers.